LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Susana Banerjee(Royal Marsden NHS Foundation Trust), George Coukos(Ludwig Cancer Research), Judith R. Kroep(Leiden University Medical Center), Corneel Coens(European Organisation for Research and Treatment of Cancer), Anita Wolfer(University of Geneva), Apostolos Sarivalasis(Centre Hospitalier Universitaire Vaudois), P.B. Ottevanger(Radboud University Nijmegen), B. Lucas(Maison des Sciences sociales et des Humanités de Dijon), Fernanda Herrera(Centre Hospitalier Universitaire Vaudois), Maureen Vanlancker(European Organisation for Research and Treatment of Cancer), Romuald Le Scodan(Centre Hospitalier privé Saint Grégoire), A.M. Westermann(Amsterdam UMC Location University of Amsterdam), Lana E. Kandalaft(Clinique de Genolier), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), M. Auvray-Kuentz(Assistance Publique – Hôpitaux de Paris)
Cited by 4
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k